Team:Evry

From 2013.igem.org

(Difference between revisions)
 
(48 intermediate revisions not shown)
Line 5: Line 5:
<div id="mainTextcontainer">
<div id="mainTextcontainer">
-
<br />
+
<h1>Welcome to the <b><span style="color:#bb8900">Iron Coli Project</span></b> Home Page</h1>
-
 
+
-
<h1>Welcome to the <b><span style="color:#bb8900">Iron Coli Project </span></b> Home Page</h1>
+
<br />
<br />
-
<p align="center"><b>The aim of our team this year is to design and realize a <em>treatment for hemochromatosis and thalassemia</em> using synthetic biology with an <em>integrated human practice</em> and <em>modeling approach</em>.</b><!p>
+
<p align="center"><b>The aim of our team this year is to design and realize a <em>treatment for hemochromatosis and thalassemia</em> using synthetic biology with an <em>integrated human practice</em> and <em>modeling approach</em>. </b></p>
<br /><br />
<br /><br />
<div>
<div>
-
 
<div style="float:right;width:49%;margin-left:1%;">
<div style="float:right;width:49%;margin-left:1%;">
<h3 align="center">The Team</h3>
<h3 align="center">The Team</h3>
-
<img src="https://pbs.twimg.com/media/BWdWUBBIMAEagNb.jpg:large" alt="team photo" width="100%"/>
+
<img src="https://static.igem.org/mediawiki/2013/8/89/IronColiTeamatthejamboree.jpg" alt="team photo" width="100%"/>
</div>
</div>
</div>
</div>
Line 26: Line 23:
<p>
<p>
-
Our project focuses on developing a novel treatment for <a href="https://2013.igem.org/Team:Evry/Project_diseases"><em>hematological disorders</em></a>  caused by an <a href="https://2013.igem.org/Team:Evry/Project_metabolism"><em/>iron overload</em></a>, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions"><em>many people cannot support</em></a>. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.
+
Our project focuses on developing a novel treatment for <a href="https://2013.igem.org/Team:Evry/Project_diseases"><em>hematological disorders</em></a>  caused by an <a href="https://2013.igem.org/Team:Evry/Project_metabolism"><em>iron overload</em></a>, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which <a href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions"><em>many people cannot support</em></a>. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.
</p>
</p>
Line 41: Line 38:
<h3 align="center">Overview of the project and the achievements</h3>
<h3 align="center">Overview of the project and the achievements</h3>
   
   
-
<div align="center" style="padding:auto">
+
<center>
 +
<div align="center">
<img align="center" id="ModMap" src="https://static.igem.org/mediawiki/2013/4/4d/IGEM_Timeline.png" width="850" class="mapper" usemap="#overview_link" style="z-index:500;"/>
<img align="center" id="ModMap" src="https://static.igem.org/mediawiki/2013/4/4d/IGEM_Timeline.png" width="850" class="mapper" usemap="#overview_link" style="z-index:500;"/>
Line 59: Line 57:
<area shape="rect" coords="633,116,841,134" target="Seminar" href="https://2013.igem.org/Team:Evry/Seminar" />
<area shape="rect" coords="633,116,841,134" target="Seminar" href="https://2013.igem.org/Team:Evry/Seminar" />
<area shape="rect" coords="633,96,841,114" target="Patients perceptions" href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" />
<area shape="rect" coords="633,96,841,114" target="Patients perceptions" href="https://2013.igem.org/Team:Evry/HumanPractice/Patients_perceptions" />
 +
 +
<!--
<area shape="rect" coords="443,457,659,474"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
<area shape="rect" coords="443,457,659,474"  href="https://2013.igem.org/Team:Evry/Model1#Results" />
<area shape="rect" coords="443,517,659,547"  href="https://2013.igem.org/Team:Evry/Model1#Conclusion" />
<area shape="rect" coords="443,517,659,547"  href="https://2013.igem.org/Team:Evry/Model1#Conclusion" />
Line 67: Line 67:
<area shape="rect" coords="164,438,419,454"  href="https://2013.igem.org/Team:Evry/Metabolism_model" />
<area shape="rect" coords="164,438,419,454"  href="https://2013.igem.org/Team:Evry/Metabolism_model" />
<area shape="rect" coords="164,418,419,434"  href="https://2013.igem.org/Team:Evry/Model3#Results" />
<area shape="rect" coords="164,418,419,434"  href="https://2013.igem.org/Team:Evry/Model3#Results" />
 +
-->
 +
<area shape="rect" coords="118,276,283,294"  target="Norms from the European Pharmacopeoa" href="https://2013.igem.org/Team:Evry/Pill_design#norm" />
<area shape="rect" coords="118,276,283,294"  target="Norms from the European Pharmacopeoa" href="https://2013.igem.org/Team:Evry/Pill_design#norm" />
<area shape="rect" coords="118,296,283,314"  target="Overcoming the acidity" href="https://2013.igem.org/Team:Evry/Pill_design#acidity" />
<area shape="rect" coords="118,296,283,314"  target="Overcoming the acidity" href="https://2013.igem.org/Team:Evry/Pill_design#acidity" />
<area shape="rect" coords="303,276,497,294"  target="Dissolution in the jejunum" href="https://2013.igem.org/Team:Evry/Pill_design#jejunum"/>
<area shape="rect" coords="303,276,497,294"  target="Dissolution in the jejunum" href="https://2013.igem.org/Team:Evry/Pill_design#jejunum"/>
<area shape="rect" coords="303,294,497,312"  target="Survival after the process" href="https://2013.igem.org/Team:Evry/Pill_design#conclusion" />
<area shape="rect" coords="303,294,497,312"  target="Survival after the process" href="https://2013.igem.org/Team:Evry/Pill_design#conclusion" />
 +
 +
<area shape="rect" coords="631,175,794,195" href="https://2013.igem.org/Team:Evry/Economy" />
 +
<area shape="rect" coords="159,402,448,423" href="https://2013.igem.org/Team:Evry/Modelmeta1" />
 +
<area shape="rect" coords="159,443,448,464" href="https://2013.igem.org/Team:Evry/Metabolism_model" />
 +
<area shape="rect" coords="159,381,448,402" href="https://2013.igem.org/Team:Evry/Modelmeta2" />
 +
<area shape="rect" coords="159,422,448,443" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
<area shape="rect" coords="159,463,448,484" href="https://2013.igem.org/Team:Evry/pop_scale" />
 +
<area shape="rect" coords="159,483,448,504" href="https://2013.igem.org/Team:Evry/Modelmeta3" />
 +
 +
<area shape="rect" coords="462,464,595,484" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,484,595,504" href="https://2013.igem.org/Team:Evry/Modeltr1" />
 +
<area shape="rect" coords="462,504,595,524" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
<area shape="rect" coords="464,524,673,558" href="https://2013.igem.org/Team:Evry/Modeltr2" />
 +
</map>
</map>
</div>
</div>
 +
</center>
Line 81: Line 98:
</div>
</div>
</div>
</div>
 +
 +
<!--
 +
<script type="text/javascript">
 +
alert("Our team is proud to announce that we were awarded a gold medal and the Best Human Practice price at the european jamboree! We are going to Boston.\n\nUnfortunately, we are missing a few thousands of euros to be capable of finishing the competition. If you are a company and would like to sponsor our team, please contact us at igemevry@gmail.com.")
 +
</script>
 +
-->
 +
</html>
</html>
{{:Team:Evry/foot}}
{{:Team:Evry/foot}}

Latest revision as of 18:38, 28 October 2013

Iron coli project

Welcome to the Iron Coli Project Home Page


The aim of our team this year is to design and realize a treatment for hemochromatosis and thalassemia using synthetic biology with an integrated human practice and modeling approach.



The Team

team photo

Abstract

Our project focuses on developing a novel treatment for hematological disorders caused by an iron overload, such as hemochromatosis and thalassemia. These autosomal recessive disorders have symptoms including cirrhosis, arthritis, and heart failure, which result from overabsorption of iron from the duodenum. Although these are among the most common heritable diseases, treatment options are limited. Even today patients are mostly treated by frequent bloodletting, which many people cannot support. The aim of our project is to combat these diseases at the source by developing a therapy that prevents the intestinal absorption of iron.

We engineer the Escherichia coli Ferric Uptake Regulation (FUR) system using a genetic inverter so that they produce siderophores (iron chelators) in response of high concentrations of iron. These engineered bacteria are delivered to the patient's intestine by encapsulating them in an ingestible polymer (capsule) that specifically degrades in the duodenum. Once released into the intestine, the bacteria respond to ambient iron by secreting elevated levels of siderophores, thereby chelating the iron to prevent its absorption by the patient.

Overview of the project and the achievements